Quick Answer
Tirzepatide is a once-weekly GIP/GLP-1 medication that's FDA-approved for chronic weight management and, as of December 2024, for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.1 In the SURMOUNT-OSA trial, adults taking tirzepatide had roughly 25 to 29 fewer breathing interruptions per hour after a year, and many improved enough to be reclassified as having mild or resolved apnea.2 Research suggests the benefit comes largely from the weight loss itself, which reduces the fat around the airway that makes it collapse during sleep. It isn't a replacement for a sleep study or, in many cases, for CPAP, and any GLP-1 needs medical supervision.
If you snore, wake up groggy, and carry extra weight, there's a real chance your sleep apnea and your weight are feeding each other. Here's the part that's genuinely new: in December 2024, tirzepatide became the first prescription drug the FDA has ever approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.1 Up until then, the go-to options were a CPAP machine, a mouthpiece, or surgery. Now there's a medication in the mix, and the trial behind it is worth understanding before you decide anything.
Why Weight and Sleep Apnea Are So Tangled
Obstructive sleep apnea happens when the soft tissue at the back of your throat relaxes during sleep and blocks your airway, over and over, all night long. Each time it happens your oxygen dips, your brain briefly wakes you up to restart your breathing, and you never really get down into the deep, restorative sleep you're after. Most people don't remember the waking. They just feel exhausted the next day and can't figure out why.
Excess weight is one of the biggest drivers, and the reason is pretty physical. Fat deposits around the neck and tongue narrow the airway, and fat around the abdomen makes the lungs work harder and reduces the volume of air you're moving. So the more weight someone carries, the more likely the airway is to collapse. That's also why losing weight has long been one of the first things sleep doctors recommend. The trouble is that apnea makes weight loss harder too, because poor sleep throws off the hormones that regulate hunger and blood sugar. It becomes a loop that's tough to break with willpower alone.
What the SURMOUNT-OSA Trial Found
SURMOUNT-OSA was the phase 3 study that got tirzepatide approved for this use, and it was published in the New England Journal of Medicine in 2024.2 Researchers ran it in two parts. One group was made up of people who weren't using a CPAP machine, and the other group was made up of people who were already on CPAP but still struggled with their apnea. Everyone in the study had moderate-to-severe OSA and obesity.
The main thing the researchers measured was the apnea-hypopnea index, or AHI, which is just the number of times per hour your breathing stops or gets shallow. Lower is better. After a year on tirzepatide, people not using CPAP saw their AHI drop by about 25 events per hour, and people who were on CPAP saw it drop by about 29 events per hour.2 Placebo, by comparison, barely moved the needle. To put that in plain terms, a lot of participants went from waking up dozens of times an hour to a fraction of that.
The bigger-picture result may matter even more. After 52 weeks, roughly 43 to 51 percent of people on tirzepatide had improved enough to be considered in remission or to have only mild, non-symptomatic apnea, versus around 14 to 15 percent on placebo.2 Participants also lost a meaningful amount of weight, in the range of 18 to 20 percent of their body weight, and saw improvements in blood pressure and inflammatory markers along the way.2 That last part lines up with what we'd expect: when the weight comes off, the airway gets more room, and the apnea eases.
So Is the Drug Treating the Apnea, or Just the Weight?
Mostly the weight, and that's an honest thing to say rather than a knock against it. The researchers found that the improvement in apnea tracked closely with how much weight people lost, which points to weight reduction as the main mechanism.2 Tirzepatide works by mimicking two gut hormones, GIP and GLP-1, that quiet appetite, slow how fast your stomach empties, and help regulate blood sugar. The weight loss that follows is what appears to relieve the physical pressure on the airway.
Why does that distinction matter to you? Because it means the same treatment that may support your sleep is also working on the metabolic problems that often travel with apnea, things like high blood pressure and insulin resistance. You're not treating one number in isolation. Still, it also means tirzepatide isn't a targeted fix aimed at the throat. If your apnea has causes beyond weight, like jaw structure or nasal issues, the medication won't address those, which is exactly why a proper diagnosis comes first.
What This Doesn't Mean
A prescription is not a reason to toss your CPAP in a drawer. In the trial, plenty of people used tirzepatide alongside CPAP, and the two together produced the strongest results.2 If you're already on CPAP and it's working, the sensible move is to keep using it and talk with your provider before changing anything. Coming off CPAP is a medical decision that should be made with a sleep specialist and confirmed with a follow-up sleep study, not something to freelance because the scale is moving.
It also isn't a shortcut around getting diagnosed. You need an actual sleep study, either at home or in a lab, to know your AHI and how severe your apnea is. Tirzepatide's approval for OSA is specifically for adults who have moderate-to-severe apnea and obesity, so the diagnosis is what tells you whether you even fit that picture.
How Defiant Approaches GLP-1 Care
At Defiant, tirzepatide is one of the medications in our medically supervised weight loss program in Lisle, IL. Every protocol starts the same way, with bloodwork, a Styku 3D body composition scan, and a provider consult, so we're working from your actual biology instead of a generic template. The program runs from $295 a month, and that price includes the medication, provider oversight, bi-weekly titration check-ins, monthly body scans, and ongoing nurse access.
The bi-weekly titration piece is where we differ from most GLP-1 telehealth services, which tend to run on a fixed monthly schedule. Checking in every two weeks lets us adjust your dose based on how you're actually responding, which is how you find the lowest effective dose while keeping side effects manageable. If sleep apnea is part of your picture, we'd want you diagnosed and, where appropriate, coordinated with your sleep provider, because the medication is one piece of a plan rather than the whole plan. We serve Lisle, Naperville, Downers Grove, Wheaton, and the western suburbs.
- Tirzepatide became the first FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.1
- In the SURMOUNT-OSA trial, adults on tirzepatide had roughly 25 to 29 fewer breathing interruptions per hour after one year, far more than placebo.2
- Roughly 43 to 51 percent of participants improved to mild or resolved apnea, and most lost about 18 to 20 percent of their body weight.2
- The benefit appears to come mainly from weight loss reducing the fat that crowds the airway, not from a direct effect on the throat.2
- Tirzepatide isn't a replacement for a sleep study or, in many cases, for CPAP, and it requires medical supervision.
Frequently Asked Questions
Lose the Weight, Breathe Easier.
Ready to work on the weight and the sleep together? Defiant's medically supervised weight loss program in Lisle starts with bloodwork, a body composition scan, and a real provider consult.
Keep Reading
Last updated August 10, 2026.